Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Taxotere

Taxotere

Taxotere is a chemotherapy medication used to treat various types of cancer, including breast, lung, and prostate cancer.
It works by interfering with the division and growth of cancer cells.
PubCompare.ai, the leading AI platform, can help optimize your Taxotere research by easily locating relevant protocols from literature, preprints, and patents, and leveraging AI-driven comparisons to identify the best protocols and products.
This can enhance the reproducibility and accuracy of your Taxotere research, leading to more reliable and effective treatment outcomes.
With PubCompare.ai's powerful tools, you can streamline your Taxotere research and make more informed decisions about treatment strategies.

Most cited protocols related to «Taxotere»

1
Pertuzumab Plus Trastuzumab and Docetaxel for HER2-Positive MBC
Cited 6 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Docetaxel ERBB2 protein, human Ethics Committees Herceptin Patients Perjeta pertuzumab Pharmacotherapy Placebos Safety Taxotere Therapies, Biological Trastuzumab
2
Apoptosis Pathway Modulation Analysis
Cited 6 times
SM-122, SM-164, SM-123, and SM-173 were synthesized using the methods described previously (30 (link)) and were determined by high-performance liquid chromatography to have >95% purity. Taxotere was purchased from the University of Michigan Hospital pharmacy. MG-132, Z-IETD-FMK, and Z-DEVD-FMK were purchased from Calbiochem. The following primary antibodies were used in the study: anti–cleaved caspase-8, anti-XIAP, and anti-PARP (Cell Signaling Technology); anti–cIAP-1 (a kind gift from John Silke, La Trobe University, Victoria, Australia); anti–cIAP-2 (R&D Systems); and anti–caspase-3, anti–caspase-9, and anti–procaspase-8 (Stressgen Biotechnologies) for Western blot analysis.
Lu J., Bai L., Sun H., Nikolovska-Coleska Z., McEachern D., Qiu S., Miller R.S., Yi H., Shangary S., Sun Y., Meagher J.L., Stuckey J.A, & Wang S. (2008). SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP. Cancer research, 68(22), 9384-9393.
Publication 2008
Antibodies benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone Caspase-8 Caspase 3 Caspase 9 High-Performance Liquid Chromatographies MG 132 Procaspase-8 SM 164 Taxotere Western Blot
3
Microtubule Nucleation and Elongation Assay
Cited 5 times
Microtubule seeds were prepared at 10 μM tubulin concentration (30% ATTO-488-labeled or ATTO-565-labeled tubulin and 70 % biotinylated tubulin) in BRB80 supplemented with 0.5 mM GMP-CPP at 37°C for 1 h. The seeds were incubated with 1 μM Taxotere (Sigma) at room temperature for 30 min and were then sedimented by high centrifugation at 30°C and resuspended in BRB80 supplemented with 0.5 mM GMP-CPP and 1 μM Taxotere. Seeds were stored in liquid nitrogen and quickly warmed to 37°C before use.
The PDMS chip was placed on a micropatterned cover glass and fixed on the microscope stage. The chip was perfused with neutravidin (25 μg/ml in BRB80; Pierce), then washed with BRB80, passivated for 20 s with PLL-g-PEG (Pll 20K-G35-PEG2K, Jenkam Technology) at 0.1 mg/ml in 10 mM Hepes (pH = 7.4), and washed again with BRB80. Microtubule seeds were flowed into the chamber at high flow rates perpendicularly to the micropatterned lines to ensure proper orientation of the seeds. Non-attached seeds were washed out immediately using BRB80 supplemented with 1% BSA. Seeds were elongated with a mix containing 14, 18, 20 or 26 μM of tubulin (30% labeled) in BRB80 supplemented with 50 mM NaCl, 50 25 mM NaPi, 1 mM GTP, an oxygen scavenger cocktail (20 mM DTT, 2 mg/ml glucose, 80 μg/ml catalase and 0.67 mg/ml glucose oxidase), 1% BSA, 0.025% methyl cellulose (1500 cp, Sigma) and 0.02% red fluorescent beads (Fluoro-Max polymer spheres, 0.52 μm diameter, Thermo Scientific). The same mix was used to subject microtubules to flow. For the experiments showing tubulin incorporation after bending, a mix was prepared with 100% labeled tubulin for bending the microtubules.
Schaedel L., John K., Gaillard J., Nachury M.V., Blanchoin L, & Théry M. (2015). Microtubules self-repair in response to mechanical stress. Nature materials, 14(11), 1156-1163.
Publication 2015
Catalase Centrifugation DNA Chips Gas Scavengers Glucose HEPES Methylcellulose Microscopy Microtubules neutravidin Nitrogen Oxidase, Glucose Oxygen Plant Embryos polylysine-graft-(poly(ethylene glycol)) Polymers Sodium Chloride Taxotere Tubulin
4
Microtubule Nucleation and Elongation Assay
Cited 5 times
Microtubule seeds were prepared at 10 μM tubulin concentration (30% ATTO-488-labeled or ATTO-565-labeled tubulin and 70 % biotinylated tubulin) in BRB80 supplemented with 0.5 mM GMP-CPP at 37°C for 1 h. The seeds were incubated with 1 μM Taxotere (Sigma) at room temperature for 30 min and were then sedimented by high centrifugation at 30°C and resuspended in BRB80 supplemented with 0.5 mM GMP-CPP and 1 μM Taxotere. Seeds were stored in liquid nitrogen and quickly warmed to 37°C before use.
The PDMS chip was placed on a micropatterned cover glass and fixed on the microscope stage. The chip was perfused with neutravidin (25 μg/ml in BRB80; Pierce), then washed with BRB80, passivated for 20 s with PLL-g-PEG (Pll 20K-G35-PEG2K, Jenkam Technology) at 0.1 mg/ml in 10 mM Hepes (pH = 7.4), and washed again with BRB80. Microtubule seeds were flowed into the chamber at high flow rates perpendicularly to the micropatterned lines to ensure proper orientation of the seeds. Non-attached seeds were washed out immediately using BRB80 supplemented with 1% BSA. Seeds were elongated with a mix containing 14, 18, 20 or 26 μM of tubulin (30% labeled) in BRB80 supplemented with 50 mM NaCl, 50 25 mM NaPi, 1 mM GTP, an oxygen scavenger cocktail (20 mM DTT, 2 mg/ml glucose, 80 μg/ml catalase and 0.67 mg/ml glucose oxidase), 1% BSA, 0.025% methyl cellulose (1500 cp, Sigma) and 0.02% red fluorescent beads (Fluoro-Max polymer spheres, 0.52 μm diameter, Thermo Scientific). The same mix was used to subject microtubules to flow. For the experiments showing tubulin incorporation after bending, a mix was prepared with 100% labeled tubulin for bending the microtubules.
Schaedel L., John K., Gaillard J., Nachury M.V., Blanchoin L, & Théry M. (2015). Microtubules self-repair in response to mechanical stress. Nature materials, 14(11), 1156-1163.
Publication 2015
Catalase Centrifugation DNA Chips Gas Scavengers Glucose HEPES Methylcellulose Microscopy Microtubules neutravidin Nitrogen Oxidase, Glucose Oxygen Plant Embryos polylysine-graft-(poly(ethylene glycol)) Polymers Sodium Chloride Taxotere Tubulin
5
HER2 Amplification Screening for BCIRG Trials
Cited 3 times
Patients in BCIRG-005/006/007 trials were screened for enrollment in one of two
central laboratories by using HER2 gene amplification status
determined by FISH as an enrollment criterion4 (link),19 (link),21 (link) (Fig 1). Those
patients whose breast cancers were HER2 amplified were eligible for
BCIRG-006 or 007, whereas those whose breast cancers were not HER2amplified were eligible for BCIRG-005 (Fig 1).
Criteria for amplified and not amplified that were initially used to screen for entry
to these trials are summarized below and in the Data Supplement.
BCIRG-006 trial (n = 3,222) is a randomized, three-arm study of adjuvant chemotherapy
with or without trastuzumab in patients with HER2-amplified stage I
to III breast cancer who were accrued between April 2001 and March 2004.4 (link) Therapy in the control arm was adjuvant
anthracycline, cyclophosphamide, and docetaxel (AC-T) with or without hormonal
therapy depending on tumor estrogen receptor and progesterone receptor status at site
investigator discretion. Therapy in the two experimental arms involved trastuzumab
(H) with patients randomly assigned to either standard AC-T adjuvant chemotherapy or
nonanthracycline chemotherapy with docetaxel and a platinum salt, again, with or
without hormonal therapy depending on tumor estrogen receptor and progesterone
receptor status. This trial demonstrated significant improvement in DFS for both
trastuzumab-containing treatment arms compared with control AC-T adjuvant
chemotherapy alone. Outcomes are summarized in the Data Supplement and reported
elsewhere.4 (link),26 BCIRG-005 clinical trial (n = 3,298) is a randomized study of concurrent (taxotere,
adriamycin, and cyclophosphamide) or sequential (AC-T) adjuvant
anthracycline-containing chemotherapy in patients with HER2-normal
(nonamplified) stage II and III breast cancer who were accrued from August 2000 to
February 2003. This trial demonstrated that sequential and combination regimens that
incorporated three drugs were equally efficacious but differed significantly in
toxicity profile. Clinical outcomes are summarized in the Data Supplement, and trial
details are reported elsewhere.19 (link),25 (link)BCIRG-007 trial (n = 263), a randomized phase III trial of docetaxel and trastuzumab
compared with docetaxel, carboplatin, and trastuzumab in women with
HER2-amplified metastatic breast cancer,24 (link) was screened for
HER2 status by FISH concurrently with BCIRG-005 and BCIRG-006.
Data for HER2 gene amplification and expression are included in the
current study; however, outcome information is not included as this trial had no
control, nontrastuzumab treatment arm (Data Supplement).
Press M.F., Sauter G., Buyse M., Fourmanoir H., Quinaux E., Tsao-Wei D.D., Eiermann W., Robert N., Pienkowski T., Crown J., Martin M., Valero V., Mackey J.R., Bee V., Ma Y., Villalobos I., Campeau A., Mirlacher M., Lindsay M.A, & Slamon D.J. (2016). HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. Journal of Clinical Oncology, 34(29), 3518-3528.
Publication 2016
Adriamycin Breast Carboplatin Chemotherapy, Adjuvant Cyclophosphamide Dietary Supplements Docetaxel Drug Combinations erbb2 Gene ERBB2 protein, human Estrogen Receptors Fishes Gene Amplification Malignant Neoplasm of Breast Neoplasm Metastasis Neoplasms Patients Pharmaceutical Adjuvants Pharmacotherapy Platinum Receptors, Progesterone Salts Staging, Cancer Taxotere Therapies, Investigational Trastuzumab Treatment Protocols Woman

Most recents protocols related to «Taxotere»

1
Proteomic Profiling of Breast Cancer
Breast tumor tissue and normal control breast tissue was excised from 23 breast cancer patients during surgery. Samples were then prepared and sequenced according to standard protocol56 (link). The women enrolled had the following demographics: 13 were post-menopausal, 4 were Estrogen Receptor (ER) negative, 16 were Human Epidermal Growth Factor Receptor (HER2) negative, 5 were Progesterone Receptor (PR) negative, 16 had invasive ductal carcinoma, and 2 had internal mammary chain involvement. Five women received treatment prior to sample collection. One woman was administered Taxotere, Carboplatin, Herceptin, Perjeta (TCHP). Three women were administered Adriamycin, cyclophosphamide, Taxol (AC-T). One woman was administered Anastrozole. Global proteomics data from primary breast tumors and matched normal tissues were generated through mass-spectrometry (MS) (PMID: 33212010)36 (link) and pre-processed as previously described (PMID: 34552204). Data pertaining to mutated and overexpressed genes in human breast cancer was also sourced from the Catalogue of Somatic Mutations In Cancer (COSMIC)16 (link). This was divided into two sets, one containing only the most commonly mutated genes in breast cancer and the other containing only unmutated, overexpressed genes in breast cancer. For weighting purposes, the number of times a gene was mutated compared to the total number of times that gene was expressed served as the weight for the first set and the number of times the gene was overexpressed was used as the weight for the second set.
Zatorski N., Sun Y., Elmas A., Dallago C., Karl T., Stein D., Rost B., Huang K.L., Walsh M, & Schlessinger A. (2023). Structural Analysis of Genomic and Proteomic Signatures Reveal Dynamic Expression of Intrinsically Disordered Regions in Breast Cancer and Tissue. bioRxiv.
Full text: Click here
Publication Preprint 2023
Adriamycin Anastrozole Breast Breast Neoplasm Carboplatin Cosmic composite resin Cyclophosphamide Diploid Cell Epidermal Growth Factor Receptor ERBB2 protein, human Estrogen Receptors Gene, Cancer Genes Herceptin Invasive Ductal Carcinoma, Breast Malignant Neoplasm of Breast Malignant Neoplasms Mammary Carcinoma, Human Mass Spectrometry Mutation Operative Surgical Procedures Patients Perjeta Postmenopause Receptors, Progesterone Specimen Collection Specimen Handling Taxol Taxotere Tissues Woman
2
HNC and Esophageal Cancer Management
In our institution, the management of HNC patients was decided by a dedicated multidisciplinary meeting involving otolaryngologists, oral surgeons, oncologists, radiation oncologists, radiologists, and pathologists. Our treatment guidelines for HNC are shown in Supplementary Figure S1 (guidelines were revised annually).
The management of patients with esophageal cancer was decided by another dedicated multidisciplinary meeting involving chest surgeons, gastrointestinal endoscopists, oncologists, radiation oncologists, radiologists, and pathologists. Treatment of patients with cTis SESCN did not necessarily have to be discussed at the meeting. For patients with SHNSESCN, the multidisciplinary esophageal team tended to recommend treating patients with HNC first, as previous clinical experience at our hospital had shown that some patients die from more advanced HNC. For patients with cTis SESCN patients, whether to treat SESCN is a matter of shared clinician–patient decision-making. The procedure of EMR was similar to the previous report and ESD to our previous publication [18 (link),19 (link)]. Generally, in our clinical practice, only those patients with cT1a SESCN were recommended for ER. Only cT1b SESCN patients who refused or were not candidates for esophagectomy were considered for ER. None of the patients in the NT group received ESCN-specific therapy, including immunotherapy. However, 16 of 17 patients received chemotherapy for HNC (14 patients received primary CCRT and 2 patients received postoperative adjuvant chemotherapy). Among these 16 patients, 12 received the PUL chemotherapy regimen; the remaining 4 received the PF regimen (3 combined with Taxotere).
Liu C.W., Chen B.H., Yeh C.J., Lee C.H., Le P.H., Tsou Y.K, & Chiu C.T. (2023). Synchronous Head and Neck Cancer and Superficial Esophageal Squamous Cell Neoplasm: Endoscopic Treatment or No Treatment for the Superficial Esophageal Neoplasm. Cancers, 15(4), 1079.
Full text: Click here
Publication 2023
CF regimen Chemotherapy, Adjuvant Chest Esophageal Cancer Esophagectomy Immunotherapy Oncologists Oral and Maxillofacial Surgeons Otolaryngologist Pathologists Patients Pharmacotherapy Radiation Oncologists Radiologist Surgeons Taxotere Therapeutics Treatment Protocols
3
Taxotere and Herceptin in HER2+ MBC
UPCI 99-058 was a phase II single-arm, open-label clinical trial of Taxotere (docetaxel) in combination to carboplatin and Herceptin (trastuzumab) in patients with HER2+ MBC. Forty patients were enrolled at the University of Pittsburgh Cancer Institute (UPCI). The study was conducted in accordance with the Declaration of Helsinki. Patients were provided with written informed consent prior to registering in the study.
The primary objective was RR. Secondary objectives were response duration (RD), time to progression (TTP), OS, percent one-year survival, and safety. Definition of response objectives and inclusion/exclusion criteria can be found in the study protocol. The present study was initiated in 1999, and therefore, measurement of lesions following RECIST was not performed.
Patient accrual followed a Simon 2-step study design. Kaplan-Meier methods were used to assess TTP and OS. Data cutoff for TTP and OS was February 18, 2020. Chi-squared tests with Yates’ correction were used to compare the distribution of clinically meaningful categorical variables. Statistical tests were performed 2-sided with an α of <0.05 to be considered statistically significant.
The study protocol (IRB#0411034) was approved by the institutional review board (IRB) and conducted in accordance with the Declaration of Helsinki. Patients were provided with written informed consent prior to registering in the study.
Gomez Marti J.L., Nasrazadani A., Ding Y., Normolle D, & Brufsky A.M. (2023). Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer. The Oncologist, 28(11), e1123-e1126.
Full text: Click here
Publication 2023
Carboplatin Disease Progression Docetaxel ERBB2 protein, human Ethics Committees, Research Herceptin Malignant Neoplasms Patients Safety Taxotere Trastuzumab
4
Genetically Heterogeneous Mouse Model for Breast Cancer
A genetically heterogeneous mouse cohort was generated by backcrossing two inbred strains as previously described (35 (link)). Briefly, we crossed the breast cancer-resistant C57BL/6 mouse strain (C57) with an FVB/N-Tg(MMTVneu)202Mul/J susceptible strain (FVB). F1-Neu+ males generated with the transgene were mated with FVB non-transgenic females to obtain a backcrossed cohort of MMTV-ErbB2 mice (BX-Neu+) (N = 147). The concentration of tail DNA was measured using a Nanodrop ND-1000 Spectrophotometer and used for genotyping. (35 (link))
Tumor cells from BX-Neu+ mice were transplanted into F1 female recipients and 100 μL of a single-cell suspension containing 2–5 ×106 cells was injected into both inguinal flanks of each mouse. Each tumor was transplanted into two individuals (N = 125). Chemotherapy was initiated when the tumor diameter reached 12 mm by treating 58 mice with docetaxel (25 mg/kg; Taxotere, Sanofi Aventis) and 69 mice with doxorubicin (5 mg/kg; Farmiblastina, Pfizer), and each drug was injected intraperitoneally (IP). Docetaxel and doxorubicin were administered every 8 and 10 days, respectively, and the mice were sacrificed when the tumor reached 25 mm in diameter or two months after the end of the treatment.
Mendiburu-Eliçabe M., García-Sancha N., Corchado-Cobos R., Martínez-López A., Chang H., Mao J.H., Blanco-Gómez A., García-Casas A., Castellanos-Martín A., Salvador N., Jiménez-Navas A., Pérez-Baena M.J., Sánchez-Martín M.A., Abad-Hernández M.D., Del Carmen S., Claros-Ampuero J., Cruz-Hernández J.J., Rodríguez-Sánchez C.A., García-Cenador M.B., García-Criado F.J., Vicente R.S., Castillo-Lluva S, & Pérez-Losada J. (2023). NCAPH Drives Breast Cancer Progression and Identifies a Gene Signature that Predicts Luminal A Tumor Recurrence. Research Square.
Full text: Click here
Publication Preprint 2023
Animals, Transgenic Breast Carcinoma Cells Docetaxel Doxorubicin Farmiblastina Females Genetic Heterogeneity Groin Males Mice, Laboratory Mouse mammary tumor virus Neoplasms Pharmaceutical Preparations Pharmacotherapy Strains Tail Taxotere Transgenes Woman
5
Establishing Bone and Lung Metastatic Models in Mice

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Animals Animals, Laboratory Arteries Body Weight Bones Cells Ethanol Food Institutional Animal Care and Use Committees Luminescence Lung Mice, Inbred BALB C Moles Mus Peptides Pharmaceutical Preparations Polysorbate 80 Powder Reconstructive Surgical Procedures Rivers Tail Taxotere Veins Woman

Top products related to «Taxotere»

1
Taxotere by Sanofi
Sourced in France, Canada, United States, Spain, Italy
Taxotere is a pharmaceutical product used in the treatment of certain types of cancer. It is a cytotoxic agent that acts by disrupting the normal function of microtubules, which are important components of cells. The core function of Taxotere is to inhibit cell division and proliferation, thereby suppressing the growth of cancer cells. Taxotere is typically administered intravenously as part of a chemotherapy regimen.
2
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
3
Docetaxel by Sanofi
Sourced in France, United Kingdom, United States, Canada, Japan
Docetaxel is a chemotherapy medication used in the treatment of various types of cancer. It is a type of taxane drug that works by interfering with the normal function of cell microtubules, thereby preventing cell division and growth.
4
Docetaxel taxotere by Sanofi
Sourced in France
Docetaxel (Taxotere) is a cytotoxic chemotherapy drug used to treat various types of cancer. It belongs to the class of drugs known as taxanes and is used to inhibit cell division and promote cell death in rapidly dividing cancer cells.
5
Model 680 by Bio-Rad
Sourced in United States, Japan, United Kingdom, China, Canada
The Model 680 is a microplate reader designed for absorbance-based assays. It can measure absorbance at multiple wavelengths and is suitable for a variety of microplate formats. The core function of the Model 680 is to quantify the absorbance of samples in a microplate, providing data for further analysis.
6
Pe annexin 5 apoptosis detection kit 1 by BD
Sourced in United States, France, Belgium, Germany, China, United Kingdom, Japan
The PE Annexin V Apoptosis Detection Kit is a laboratory equipment product designed for the detection of apoptosis. It utilizes the binding properties of Annexin V, a calcium-dependent phospholipid-binding protein, which has a high affinity for phosphatidylserine (PS). The kit provides a method to identify apoptotic cells by flow cytometry.
7
2 3 4 dihydroxyphenyl ethylamine dopamine hydrochloride by Merck Group
Sourced in United States
2-(3,4-dihydroxyphenyl) ethylamine (dopamine) hydrochloride is a chemical compound that serves as a neurotransmitter in the central nervous system. It is a crystalline solid that is soluble in water and is used as a reference standard in various analytical and research applications.
8
Trypsin edta by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, Canada, Switzerland, France, China, Australia, Japan, Italy, Spain, New Zealand, Sweden, Singapore, Portugal, Thailand, Belgium, Denmark, Taiwan, Province of China, Ireland, Brazil, Netherlands, Austria, Czechia, India, Morocco, Israel, Poland, Macao
Trypsin-EDTA is a solution used in cell culture applications to dissociate adherent cells from their growth surface. It contains the proteolytic enzyme trypsin and the chelating agent EDTA, which work together to break down the cellular adhesions and allow the cells to be harvested and passaged.
9
Facsaria dual laser flow cytometer by BD
The FACSAria dual laser flow-cytometer is a laboratory instrument used for the analysis and sorting of cells or particles in a fluid suspension. It utilizes two laser sources to excite fluorescent labels within the sample, enabling the detection and separation of specific cell populations based on their physical and fluorescent properties.
10
Endoxan by Baxter
Sourced in Germany, United States, Switzerland
Endoxan is a laboratory equipment product manufactured by Baxter. It is a device used for the preparation and administration of pharmaceutical solutions. The core function of Endoxan is to provide a controlled and sterile environment for the handling and delivery of medical substances.

More about "Taxotere"

Taxotere, a chemotherapeutic agent, is a widely used treatment for various cancers, including breast, lung, and prostate cancer.
This taxane-based drug works by disrupting the normal division and growth of cancer cells, leading to their death.
Docetaxel, the active ingredient in Taxotere, is a semisynthetic compound derived from the European Yew tree.
Taxotere has been shown to be effective in combination with other chemotherapeutic agents, such as Endoxan, and can be administered intravenously.
Researchers and clinicians often use Fetal Bovine Serum (FBS) as a growth supplement for cell cultures, including those used in Taxotere research.
FBS provides essential nutrients and growth factors that support the proliferation and survival of cells in vitro.
Additionally, tools like the PE Annexin V Apoptosis Detection Kit I and flow cytometry devices, such as the FACSAria dual laser flow-cytometer, are utilized to assess the effects of Taxotere on cell viability and apoptosis.
PubCompare.ai, the leading AI platform, can streamline and optimize Taxotere research by providing access to relevant protocols from the literature, preprints, and patents.
This AI-driven tool enables researchers to identify the most effective Taxotere-based treatment strategies, enhancing the reproducibility and accuracy of their findings.
By leveraging PubCompare.ai's powerful capabilities, researchers can make more informed decisions about Taxotere-based treatment approaches, potentially leading to improved patient outcomes.
Furthermore, Taxotere research may also involve the use of 2-(3,4-dihydroxyphenyl) ethylamine (dopamine) hydrochloride, a chemical compound that can be used to study the cellular mechanisms underlying the effects of Taxotere.
Additionally, Trypsin-EDTA, a proteolytic enzyme, is often used in cell culture experiments to detach and dissociate cells, which is a crucial step in Taxotere-related studies.